Mancini Anthony sold $743K of RVMD
Mancini Anthony (See Remarks) sold 3,708 shares of Revolution Medicines, Inc. (RVMD) at an average of $200.45 ($200.00–$200.54, $0.74M total) across 2 trades over 2026-09-24 to 2026-09-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership and may influence short‑term price dynamics.
Market read
Insider sell of $743K by an officer is a modest but noteworthy event for RVMD shareholders.
What to watch
The 10b5‑1 plan pre‑arranged nature may limit interpretive weight.
Background
Form 4 filings disclose insider transactions; this is the first public report of this sale.
Ticker impact
Officer Mancini Anthony sold 3,708 shares for $743K via a 10b5‑1 plan, reducing his stake to 39,765 shares.
likely downward pressure as the market prices the insider sell
A $743K sale by an officer is material for a small‑cap biotech and can prompt short‑term selling pressure.
Market effects
May raise concerns for biotech sector investors tracking insider activity.
Limited to US biotech investors.
Minimal
Counterpoint
The sale could be a routine liquidity move, not a negative signal.
Key entities
- CompanyRevolution Medicines, Inc.
US‑listed biotech (ticker RVMD) subject of the insider sale.
- PersonMancini Anthony
Officer at Revolution Medicines who executed the sale.
